FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	OVAL	
OMB Number:	3235-0	287
Estimated average	burden	
nours per response	e	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)																
1. Name and Address of Reporting Person* Touchon Pascal					2. Issuer Name and Ticker or Trading Symbol Atara Biotherapeutics, Inc. [ATRA]							5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900					3. Date of Earliest Transaction (Month/Day/Year) 11/16/2021								X Officer (give title below) Other (specify below) President and CEO					
(Street) SOUTH SAN FRANCISCO, CA 94080				4. If	4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City		(State)	(Zip)		Table I - Non-Derivative Securities Ad						cquir	uired, Disposed of, or Beneficially Owned						
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea		Execu any	2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr. 8)		4. Securities Acquire (A) or Disposed of ((Instr. 3, 4 and 5)		of (D	D) Benefic Reporte		ount of Securities cially Owned Following ed Transaction(s) 3 and 4)		Direct (D)	Beneficial Ownership			
						Со	de	V	Amount	(A) or (D)	Pric	ce		(I)		or Indirect (I) (Instr. 4)	(Instr. 4)	
Common	Stock		11/16/2021			S	1)		8,402	D	\$ 17.13 (2)	169	9 328,489		D			
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. Persons who respond to the collection of information SEC 1474 (9-0) contained in this form are not required to respond unless the form displays a currently valid OMB control number. Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned)2)										
1. Title of	2	3. Transaction	on 3A. Deem		puts, calls, v	5.	its, op						le and	8 Price of	9. Number	of 10.	11. N	Jature
Derivative Security	Conversion or Exercise Price of Derivative Security		Execution any	Date, if	Transaction Code (Instr. 8)	Num of Deriv	vative rities nired or osed 0) r. 3,	and Expiration Date (Month/Day/Year) And Expiration Date (Month/Day/Year)		Amor Unde Secur (Instr	unt of orlying rities : 3 and		Derivative Derivative Securities Beneficiall Owned Following Reported Transaction (Instr. 4)	Owners Form o Derivat Securit Direct (or India	hip of Indire Benefici Ownersh (Instr. 4)	direct ficial ership		
					Code V	(A)	(D)	Da Ex	ate ercisable	Expira Date	ntion	Title	Amount or Number of Shares					

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Touchon Pascal C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BLVD., SUITE 900 SOUTH SAN FRANCISCO, CA 94080	X		President and CEO					

Signatures

/s/ David Tucker, Attorney-in-Fact for Pascal Touchon	11/18/2021
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units.
- The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. The prices actually received ranged from \$16.45 to \$17.3823. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold on behalf of the group at each price within the range.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.